Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Public ClinicalTrials.gov record NCT03073473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment. It, however, remains unclear if these new diagnostic technologies truly influence clinical and economic outcomes. This study will evaluate if patients treated according to the results of the NantHealth GPS Cancer test achieve optimal outcomes compared to patients whose treatment are discordant with GPS Cancer recommendations.
Study identification
- NCT ID
- NCT03073473
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2017 (Actual)
- Primary completion
- Jun 13, 2018 (Actual)
- Completion
- Jun 13, 2018 (Actual)
- Last update posted
- Jul 20, 2018
2017 – 2018
United States locations
- U.S. sites
- 10
- U.S. states
- 1
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| RCCA - Central Jersey Division | East Brunswick | New Jersey | 08816 | — |
| RCCA - Freehold Division | Freehold | New Jersey | 07728 | — |
| Hackensack Meridian Health System | Hackensack | New Jersey | 07601 | — |
| RCCA - Hackettstown Division | Hackettstown | New Jersey | 07840 | — |
| RCCA - Howell Division | Howell Township | New Jersey | 07731 | — |
| RCCA - Little Silver Division | Little Silver | New Jersey | 07739 | — |
| RCCA - Marmora Division | Marmora | New Jersey | 08223 | — |
| RCCA - Mount Holly Division | Mount Holly | New Jersey | 08060 | — |
| RCCA - Pompton Plains Division | Pompton Plains | New Jersey | 07444 | — |
| RCCA - Sparta Division | Sparta | New Jersey | 07871 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03073473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03073473 live on ClinicalTrials.gov.